"10.1371_journal.pone.0099276","plos one","2014-06-09T00:00:00Z","Andreas Clemens; Herbert Noack; Martina Brueckmann; Gregory Y H Lip","Center for Thrombosis and Hemostasis (CTH), University Medical Center Mainz, Mainz, Germany; Global Biostatistics and Data Management, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany; Corporate Division Medicine, Global Therapeutic Area Cardiovascular, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany; Faculty of Medicine Mannheim, University of Heidelberg, Mannheim, Germany; University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, United Kingdom","Conceived and designed the experiments: AC HN MB GYHL. Performed the experiments: AC HN MB GYHL. Analyzed the data: AC HN MB. Contributed reagents/materials/analysis tools: AC HN MB GYHL. Wrote the paper: AC HN MB GYHL.","AC HN and MB are employees of Boehringer Ingelheim Pharma GmbH & Co. KG. GYHL has served as a consultant for Bayer, Astellas, Merck, Sanofi, BMS/Pfizer, Daiichi-Sankyo, Biotronik, Portola, and Boehringer Ingelheim and has been on the speakers bureau for Bayer, BMS/Pfizer, Boehringer Ingelheim, and Sanofi Aventis. There are no patents or products in development to declare. Boehringer Ingelheim markets dabigatran etexilate. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials.","2014","06","Andreas Clemens","AC",4,TRUE,4,4,3,4,TRUE,TRUE,FALSE,0,NA,FALSE
